Previous Close | 2.6600 |
Open | 2.5500 |
Bid | 2.5700 x 100 |
Ask | 2.7000 x 100 |
Day's Range | 2.5500 - 2.8200 |
52 Week Range | 2.3500 - 44.8000 |
Volume | |
Avg. Volume | 1,451,210 |
Market Cap | 4.085M |
Beta (5Y Monthly) | 0.38 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients.
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q4 2023 Earnings Call Transcript March 8, 2024 Bio-Path Holdings, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome to the Bio-Path Holdings Full Year 2023 Earnings Conference Call. […]
Q4 2023 Bio Path Holdings Inc Earnings Call